The Committee will discuss a biologics license application (BLA) 761222, for Sintilimab injection, submitted by Innovent Biologics (Suzhou) for the first-line treatment of patients with Stage IIIB, IIIC, or Stage IV non-squamous Non-small cell lung cancer with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations.
Back to All Events
Earlier Event: December 8
Cardiovascular and Renal Drugs Advisory Committee
Later Event: February 15
Vaccines and Related Biological Products Advisory Committee